Subscribe To
AVXL / This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
AVXL News
By Seeking Alpha
October 9, 2023
Anavex: The September Data
Anavex Life Sciences Corp. presented follow-on data from its Alzheimer's disease trial. This data uses a statistical methodology that is difficult to more_horizontal
By GlobeNewsWire
August 1, 2023
Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023
Webcast and Conference Call To be Held Tuesday, August 8, 2023, 8:30 am ET Webcast and Conference Call To be Held Tuesday, August 8, 2023, 8:30 am ET more_horizontal
By Seeking Alpha
July 18, 2023
Anavex: Will Be An Interesting Endgame To Watch
Not much has happened at Anavex Life Sciences Corp. since my last coverage in March. There are a few pieces of news, which I cover here. The toplining more_horizontal
By Proactive Investors
June 30, 2023
Anavex Life Sciences' Rett syndrome treatment impresses analysts
Anavex Life Sciences (NASDAQ:AVXL) Corp announced earlier this week that its Rett syndrome treatment showed a disease-modifying effect in a long-term more_horizontal
By GlobeNewsWire
June 20, 2023
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmac more_horizontal
By Zacks Investment Research
June 8, 2023
Is Anavex Life Sciences (AVXL) Outperforming Other Medical Stocks This Year?
Here is how Anavex Life Sciences (AVXL) and Clene Inc. (CLNN) have performed compared to their sector so far this year. more_horizontal
By Seeking Alpha
June 6, 2023
Anavex's Blarcamesine: Sigma-1 Receptor Agonists And Antioxidants For Alzheimer's Disease
Blarcamesine, a sigma-1 receptor agonist, may be a more effective antioxidant than Aricept and galantamine in treating Alzheimer's disease. If granted more_horizontal
By Zacks Investment Research
May 31, 2023
Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 338.45%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 338.5% in Anavex Life Sciences (AVXL). While the effectivenes more_horizontal